Targeting CPT1a has shown remarkable anti-leukemia activity: A novel CPT1a inhibitor ST1326 has been proved effective on leukemia cell lines and primary cells obtained from patients with hematologic malignancies [8]. Here, CPT1A is linked to hematologic disorder.